Left atrial appendage closure: A therapy uniquely suited for specific populations of patients with atrial...

Area of Science:

• Cardiology
• Medical Devices
• Clinical Trials

Background:

• Atrial fibrillation (AF) is a common arrhythmia increasing stroke risk.
• Cardioembolic stroke in AF patients is preventable with oral anticoagulation (OAC).
• The WATCHMAN device offers an alternative to OAC for stroke prevention.

Purpose of the Study:

• To compare the efficacy and safety of WATCHMAN left atrial appendage closure (LAAC) with oral anticoagulation (OAC).
• To identify patient populations where LAAC may be preferable to direct-acting oral anticoagulants (DOACs).

Main Methods:

• The PROTECT and PREVAIL trials evaluated the WATCHMAN LAAC device combined with short-term warfarin.
• Comparison was made against long-term warfarin therapy for stroke, cardiovascular death, and systemic embolism.
• Analysis considered specific AF populations with contraindications or risks associated with OACs.

Main Results:

• WATCHMAN LAAC with short-term warfarin was noninferior to long-term warfarin for the composite endpoint.
• WATCHMAN LAAC demonstrated a significant reduction in life-threatening bleeding compared to OAC.
• LAAC is a viable alternative for AF patients unsuitable for or intolerant to OACs.

Conclusions:

• Left atrial appendage closure is a safe and effective stroke-preventive strategy in AF patients.
• LAAC offers significant bleeding reduction compared to OAC, particularly in high-risk populations.
• Further research is needed to explore DOACs for device-related thrombosis and compare DOACs with LAAC in specific AF subgroups.